Vet Pathol Download to Citation Manager
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ramalho, L. N. Z.
Right arrow Articles by Zucoloto, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ramalho, L. N. Z.
Right arrow Articles by Zucoloto, S.
Vet Pathol 43:424-429 (2006)
© 2006 American College of Veterinary Pathologists

The Expression of p63 and Cytokeratin 5 in Mixed Tumors of the Canine Mammary Gland Provides New Insights into the Histogenesis of These Neoplasms

L. N. Z. Ramalho, A. Ribeiro-Silva, G. D. Cassali and S. Zucoloto

Department of Pathology, Faculty of Medicine of Ribeirão Preto, University of São Paulo, Ribeirão Preto, SP, Brazil (LNZR, ARS, SZ), and Department of General Pathology, Institute of Biological Science, Federal University of Minas Gerais, Brazil (GDC)


   Abstract
Top
 Abstract
Materials and Methods
 Results
 Discussion
 Acknowledgements
 References
 
Cytokeratin 5 and p63 have been described as basal and myoepithelial cell markers in human breast. Mixed tumors of the canine mammary gland have been associated with a myoepithelial origin. Cytokeratin 5 expression has not been evaluated in these tumors. We investigated the relation between cytokeratin 5 and p63 double-immunohistochemical expression in 23 mixed tumors of the canine mammary gland (10 benign mixed tumors and 13 carcinomas arising from benign mixed tumors) and their origin. Cytokeratin 5 and p63 co-expression was observed in myoepithelial cells of benign mixed tumors, as well as in squamous differentiation of carcinoma arising from benign mixed tumors. Though a few interstitial spindle cells of the mesenchymal components expressed both p63 and cytokeratin 5, the basal epithelial cells were labeled only by cytokeratin 5. The co-expression of p63 and cytokeratin 5 in myoepithelial cells and squamous differentiation suggest that, like in human breast, cytokeratin 5 can also be considered a myoepithelial- and squamous-cell differentiating marker in canine tumors. The presence of some interstitial spindle cells stained for p63 and cytokeratin 5 might be associated with a myoepithelial origin of the mesenchymal component of mixed tumors of the canine mammary gland. Moreover, contrary to p63, basal epithelial cells were labeled by cytokeratin 5, indicating that cytokeratin 5 may not represent an exclusive myoepithelial cell marker but also a basal epithelial cell marker in canine mixed tumors. According to these data, basal epithelial cells may be related to the origin of the epithelial component of mixed tumors of the canine mammary gland.

Key words: Canine; cytokeratin 5; mammary; p63; tumor.

The mixed tumors of the canine mammary gland are a heterogeneous group of neoplasms with incompletely known histogenesis, which frequently leads to different classifications and terminologies. It seems likely that mixed tumors are of myoepithelial origin.9,10 Benign mixed tumors (BMT) are neoplasms composed of benign cells morphologically resembling epithelial components (luminal and/or myoepithelial) and mesenchymal cells that produce cartilage and/or bone and/or fat, eventually in combination with fibrous tissue.17 The carcinomas arising from BMTs (CBMT) of the canine mammary gland are neoplasms composed of carcinomatous cells occurring in a benign mixed tumor.17

In the normal mammary gland, 3 cell populations can be recognized, each with a distinct immunoprofile. The luminal layer is composed of glandular epithelial cells, which are labeled by cytokeratins 7, 8, 18, and 19; and basal epithelial cells, which are labeled by cytokeratins 5, 14, 17, but not smooth muscle alpha-actin ({alpha}SMA). The basal layer is composed of myoepithelial cells expressing cytokeratins 5, 14, 17, in addition to p63 and {alpha}SMA.13 In the mammary neoplasms, these 3 cell types can become limited to 2 or 1, characterizing particular kinds of neoplasms.1,13 Recently, cytokeratin 5 (CK5) has been reported to be not only a myoepithelial cell marker but also a progenitor cell marker in breast neoplasms.5,6 However, CK5 expression has not yet been evaluated in mixed tumors of the canine mammary gland.

p63, a homologue of the p53 gene, has been described as a nuclear transcriptional factor, with diverse functions in the cell cycle ranging from apoptosis to cell differentiation.7,15,28,32 p63 has also been associated with the development of various epithelial neoplasms.2,7,21,31 p63 expression was observed in myoepithelial cells of benign neoplasms and in low differentiated carcinomatous cells of human breast.3,4,19,20,23,24,27,30 Moreover, p63 has been proposed to be an important myoepithelial cell marker that serves to define benign and malignant lesions and may indicate a myoepithelial histogenesis in some tumors of the canine mammary gland.9 Nevertheless, the cellular origin of mixed tumors of the canine mammary gland and the reason why carcinomas develop into benign mixed tumors are still unclear. Therefore, the aim of the present study was to determine the relation between p63 and CK5 expressions in mixed tumors of the canine mammary gland in an attempt to clarify the histogenesis of these neoplasms.


   Materials and Methods
Top
 Abstract
 Materials and Methods
Results
 Discussion
 Acknowledgements
 References
 
Casuistic

Twenty-three cases of canine mammary gland tumors were retrieved from the files of the Laboratory of Comparative Pathology, Department of General Pathology, Institute of Biological Science, Federal University of Minas Gerais, Brazil. The selection was based on the histopathologic diagnosis according to World Health Organization criteria.17 The histologic types selected were as follows: benign mixed tumors (n = 10) and carcinoma arising from benign mixed tumors (n = 13). All dogs were females, ranging in age from 5 to 15 years (mean, 11 years); the diameter of the mammary tumors ranged from 4 to 25 cm (mean, 11 cm). However, the age of the dogs was not related to the size of the neoplastic masses. All dogs presented with single neoformations. The dogs were not sterilized. None of the animals had received any treatment before the biopsy procedure.

Immunohistochemistry

All tissue samples were routinely fixed in 4% neutral formalin and embedded in paraffin. Briefly, 3-µm-thick sections were cut from paraffin blocks containing representative tumor samples. Paraffin sections were dewaxed in xylene, rehydrated through a graded alcohol series, placed in 10 mM citrate buffer, and submitted to heat retrieval by using a vapor lock for 40 minutes. After heating, the slides were allowed to cool to room temperature and were briefly washed with Tris-buffered saline solution. Endogenous peroxidase activity was blocked with 3% hydrogen peroxide in methanol for 5 minutes. Normal serum (Novostain Super ABC kit, Novocastra Laboratories, Newcastle Upon Tyne, UK) was used for 30 minutes to block nonspecific immunoassaying. Immunohistochemical staining was performed by using an avidin-biotin peroxidase system (Novocastra). The following primary antibodies were incubated overnight at room temperature: p63 (1 ° 200, clone 4A4, Santa Cruz, USA), CK5 (1 ° 200, clone XM26; Novocastra), multicytokeratin (AE1/AE3) (1 ° 100, clones AE1 and AE3; Novocastra), alpha smooth muscle actin ({alpha}SMA) (1 ° 100, clone {alpha}sm-1, Novocastra, UK), and vimentin (VIM) (1 ° 100, clone V9, Novocastra, UK). After washes in phosphate-buffered saline solution (PBS), biotinylated universal secondary antibody (Novocastra) was applied for 30 minutes. The sections were incubated with the avidin-biotin complex reagent (Novocastra) for 30 minutes and were developed with 3.3-diaminobenzidine tetrahydrochloride (DAB) in PBS, pH 7.5, containing 0.036% hydrogen peroxide, for 5 minutes. Light Mayer's hematoxylin was applied as a counterstain. The slides were then dehydrated in a series of ethanols and mounted with Permount (Fischer, Fairlawn, NJ, USA).

Cytokeratin 5-positive tumors were submitted to a double-immunolabeling study according to the manufacturer's protocol (EnVision Doublestain System, Dako, Denmark). For this purpose, we used CK5 (1 ° 200, clone XM26; Novocastra) with p63 (1 ° 200, clone 4A4; Santa Cruz Biotechnology, Santa Cruz, USA). p63 (nuclear marker) was developed with DAB (brown), and the CK5 (cytoplasmic marker) was developed with fast red (red).

Normal skin was used as the positive control for p63, and normal mammary tissue was used as the positive control for CK5 and AE1/AE3. A uterine leiomyoma was used as the positive control for {alpha}SMA and VIM. The external controls were obtained from canine tissue. Regardless of the external controls, all samples exhibited internal controls: normal skin and mammary tissue. Negative controls for immunostaining were prepared by omission of the primary antibody.

Tumors were considered to be positive when distinct brown nuclear (p63) or cytoplasmic (CK5, AE1/AE3, {alpha}SMA, and VIM) staining was present homogenously. The number of immunoreactive cells was assessed semiquantitatively, in 30 fields chosen randomly, at high power (x400): 0 = no stained cells; ± = less than 10% positive cells; + = 10–50% positive cells; and ++ = more than 50% positive cells.9 AE1/AE3, {alpha}SMA, and VIM were used only to confirm the histologic patterns of the tumors.

Statistical analysis

Statistical analysis was performed by using the Graph Pad Prism v.3 software (San Diego, CA). The relation between p63 and CK5 expression and the histologic diagnosis was determined by the Fisher test. All tests were 2 tailed, and a P value of <0.05 was considered to be significant.


   Results
Top
 Abstract
 Materials and Methods
 Results
Discussion
 Acknowledgements
 References
 
Benign mixed tumors were characterized as tumors composed of benign cells morphologically resembling epithelial components (luminal and/or basal) and mesenchymal cells that have produced cartilage and/or bone in association with fibrous tissue. Carcinomas arising from BMTs were distinguished as individual nodules of malignant epithelial cells, the majority of them presenting a squamous appearance, with individual keratinization and pearls formations, occurring in BMTs. The data regarding immunolabeling for AE1/AE3, {alpha}SMA, and VIM in BMT and CBMT are presented in Table 1. The immunolabeling for p63 and CK5 is presented in Table 2.


View this table:
[in this window]
[in a new window]
  		Table 1 Immunoreactivity for cytokeratins(AE1/AE3), alpha smooth muscle actin ({alpha}SMA), and vimentin (VIM) of benign mixed tumors (BMT) and carcinomas arising from benign mixed tumors (CBMT) of the canine mammary gland.*

 

View this table:
[in this window]
[in a new window]
  		Table 2 Immunoreactivity forp63 and CK5 antibodies of benign mixed tumors (BMT) and carcinomas arising from benign mixed tumors (CBMT) of the canine mammary gland.*

 
In BMT, most epithelial cells (glandular and basal) stained for the pool of cytokeratins AE1/AE3. Only the basal cells, however, showed a weak immunolabeling for CK5. All the myoepithelial cells from BMT expressed CK5, AE1/AE3, {alpha}SMA, and VIM. The majority of interstitial spindle cells in the mesenchymal component expressed {alpha}SMA and VIM, but only some of them expressed CK5 and AE1/AE3. Chondrocytes and osteoblasts were labeled only by VIM.

In CBMT, many epithelial cells (glandular and basal phenotype) were labeled by AE1/AE3. Only the basal cells stained for CK5. The areas of squamous differentiation in CBMT presented immunolabeling for both AE1/AE3 and CK5. The interstitial spindle cells, chondrocytes, and osteoblasts from the mesenchymal component of CBMT, which is benign, had an immunolabeling profile similar to BMT.

There was a strong relation between CK5 and p63 expression in the myoepithelial cells of BMT (P = 0.041), as well as in areas of squamous differentiation of CBMT (P = 0.026). In BMT and CBMT, a few spindle cells of the mesenchymal component expressed both p63 and CK5, but these markers were not expressed by chondrocytes or osteoblasts. Moreover, some epithelial cells with a basal phenotype expressed CK5 in BMT and CBMT, but none of them presented immunolabeling for p63 (Figs. 1–4).


Figure 01
View larger version (141K):
[in this window]
[in a new window]
  		Fig. 1 Mammary gland; Canis familiaris, case No 4. Benign mixed tumor with both basal epithelial and myoepithelial CK5-positive cells stained in red (cytoplasm), and p63-positive myoepithelial cells stained in brown (nucleus). Double immunolabeling method, CK5 and p63. Bar = 100 µ.
Fig. 2. Mammary gland; Canis familiaris, case No 4. Benign mixed tumor showing some interstitial spindle cells in the mesenchymal component stained for CK5 (cytoplasmic staining, red) and p63 (nuclear staining, brown). Double immunolabeling method, CK5 and p63. Bar = 100 µ.
Fig. 3. Mammary gland; Canis familiaris, case No 11. Carcinoma arising from benign mixed tumor showing positivity for CK5 only in the basal epithelial cells (cytoplasmic staining, red). Double immunolabeling method, CK5 and p63. Bar = 100 µ.
Fig. 4. Mammary gland; Canis familiaris, case No 11. Carcinoma arising from a benign mixed tumor showing cells with squamous differentiation positive for both CK5 (cytoplasmic staining, red) and p63 (nuclear staining, brown). Double immunolabeling method, CK5 and p63. Bar = 100 µ.

 

   Discussion
Top
 Abstract
 Materials and Methods
 Results
 Discussion
Acknowledgements
 References
 
p63, a homologue of the p53 gene, is located on chromosome 3q27. This gene product is crucial for the maintenance of a stem-cell population in several epithelial tissues and is necessary for the normal development of epithelial organs,16 including mammary glands.31 Besides being expressed in the basal epithelial cells of other organs (e.g., skin, cervix, and prostate),7,25,31 p63 is also expressed in the nuclei of myoepithelial cells of normal breast ducts and lobules.3,4,19,20,23,24,27,30 Cytokeratin 5, also known as CK5, is a 58 kD protein found in basal epithelial cells of different tissues, including epidermis, hair follicles, sebaceous and sweat glands, tongue, vagina, urothelium, prostate, and breast.1 Cytokeratin 5 can also be detected in myoepithelial cells of normal breast.8,13

p63 is overexpressed in several primary human epithelial tumors, a fact indicating a possible role for p63 in the growth and the development of these tumors.2,7,21,31 This overexpression occurs mainly in squamous carcinomas, suggesting that p63 may act as an oncogene in this kind of neoplasm.11 Like p63, CK5 stained the poorly differentiated areas, as well as the foci of squamous differentiation, suggesting that these markers may be used together in immunohistochemical panels to characterize squamous differentiation in poorly differentiated carcinomas.11 In the present study, the strong relation between the expression of p63 and CK5 in myoepithelial cells of BMT, as is the case for human breast,14 suggests that CK5 can also be considered a myoepithelial cell marker in the canine mammary gland and may be useful to discriminate benign neoplasms from malignancies in canine tumors.

p63 and other myoepithelial cell markers have been described in matrix-producing and metaplastic carcinomas of the human breast, suggesting that these tumors exhibit myoepithelial cell differentiation.12,14 p63 has been reported to be a valuable marker of myoepithelial cells in tumors of the canine mammary gland, suggesting a myoepithelial histogenesis of these tumors.9 Our data show that the presence of some interstitial spindle cells of the mesenchymal component in BMT and CBMT expressing p63 and CK5, both known as myoepithelial cell markers in human breast, may reinforce the hypothesis of a myoepithelial origin of the mesenchymal component in mixed tumors of the canine mammary gland.

Though CK5 is considered to be a myoepithelial and a basal epithelial cell marker in the normal human breast, there is a subset of human-breast carcinomas that express CK5. The expression of CK5 indicates a basal epithelial phenotype1,5,6,18 and is associated with a poor prognosis in human breast carcinomas.22,26,29 These CK5-positive cells were shown to represent progenitor or adult stem cells that give rise to the glandular and myoepithelial cell lineage.5,6 A strong relation between CK5 and p63 expression was recently observed in human-breast carcinomas, indicating that p63, like CK5, may be considered a marker for the basal phenotype of breast cancer.22 However, our findings did not demonstrate co-expression of p63 and CK5 in basal epithelial cells in either BMT or CBMT. Moreover, basal epithelial cells were labeled by CK5 in BMT and mainly in CBMT, with no p63 labeling. CK5 may not represent an exclusive myoepithelial-cell marker in canine mixed tumors but rather a basal epithelial cell marker, such as occurs in the human breast. Probably basal epithelial cells may be related to the origin of the epithelial component of mixed tumors of the canine mammary gland.

In conclusion, because the three cellular phenotypes observed in normal mammary glands can be lost and converted to new phenotypes in mammary cancer, they may or may not present their original immunoprofile. It is possible that in breast cancer the basal phenotype preserves a myoepithelial immunoprofile, in contrast to mixed tumors of the canine mammary gland, in which p63 may represent a myoepithelial origin of the mesenchymal component and the epithelial component may originate from basal epithelial cells that exhibit CK5 expression. It is possible that mixed tumors of the canine mammary gland have components originating from common stem cells with a higher capacity for divergent differentiation than human breast cancer.


   Acknowledgements
Top
 Abstract
 Materials and Methods
 Results
 Discussion
 Acknowledgements
References
 
This research was supported by a grant from Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP 03/02532-8). The authors wish to thank Auristela de Mello Martins for technical assistance.


   References
Top
 Abstract
 Materials and Methods
 Results
 Discussion
 Acknowledgements
 References
 

  1. Abd El-Rehim DM, Pinder SE, Paish CE, Bell J, Blamey RW, Robertson JF, Nicholson RI, Ellis IO. Expression of luminal and basal cytokeratins in human breast carcinoma. J Pathol 203:661–671, 2004[CrossRef][ISI][Medline]
  2. Au NH, Gown AM, Cheang M, Huntsman D, Yorida E, Elliott WM, Flint J, English J, Gilks CB, Grimes HL. P63 expression in lung carcinoma: a tissue microarray study of 408 cases. Appl Immunohistochem Mol Morphol 12:240–247, 2004[ISI][Medline]
  3. Barbareschi M, Pecciarini L, Cangi MG, Macri E, Rizzo A, Viale G, Doglioni C. P63, a p53 homologue, is a selective nuclear marker of myoepithelial cells of the human breast. Am J Surg Pathol 25:1054–1060, 2001[CrossRef][ISI][Medline]
  4. Batistatou A, Stefanou D, Arkoumani E, Agnantis NJ. The usefulness of p63 as a marker of breast myoepithelial cells. In Vivo 17:573–576, 2003[ISI][Medline]
  5. Boecker W, Moll R, Dervan P, Buerger H, Poremba C, Ina Diallo R, Herbst H, Schmidt A, Lerch MM, Buchwalow IB. Usual ductal hyperplasia of the breast is a committed stem (progenitor) cell lesion distinct from atypical ductal hyperplasia and ductal carcinoma in situ. J Pathol 198:458–467, 2002[CrossRef][ISI][Medline]
  6. Boecker W, Moll R, Poremba C, Holland R, Van Diest PJ, Dervan P, Burger H, Wai D, Ina Diallo R, Brandt B, Herbst H, Schmidt A, Lerch MM, Buchwallow IB. Common adult stem cells in the human breast give rise to glandular and myoepithelial cell lineages: a new cell biological concept. Lab Invest 82:737–746, 2002[ISI][Medline]
  7. Di Como CJ, Urist MJ, Babayan I, Drobnjak M, Hedvat CV, Teruya-Feldstein J, Pohar K, Hoos A, Cordon-Cardo C. p63 expression profiles in human normal and tumor tissues. Clin Cancer Res 8:494–501, 2002[Abstract/Free Full Text]
  8. Dunne B, Lee AH, Pinder SE, Bell JA, Ellis IO. An immunohistochemical study of metaplastic spindle cell carcinoma, phyllodes tumor and fibromatosis of the breast. Hum Pathol 34:1009–1015, 2003[CrossRef][ISI][Medline]
  9. Gama A, Alves A, Gartner F, Schmitt F. P63: a novel myoepithelial cell marker in canine mammary tissues. Vet Pathol 40:412–420, 2003[Abstract/Free Full Text]
  10. Gärtner F, Geraldes M, Cassali G, Rema A, Schmitt F. DNA measurement and immunohistochemical characterization of epithelial and mesenchymal cells in canine mixed mammary tumours: putative evidence for a common histogenesis. Vet J 158:39–47, 1999[CrossRef][ISI][Medline]
  11. Kaufmann O, Fietze E, Mengs J, Dietel M. Value of p63 and cytokeratin 5/6 as immunohistochemical markers for the differential diagnosis of poorly differentiated and undifferentiated carcinomas. Am J Clin Pathol 116:823–830, 2001[CrossRef][ISI][Medline]
  12. Koker MM, Kleer CG. P63 expression in breast cancer: a highly sensitive and specific marker of metaplastic carcinoma. Am J Surg Pathol 28:1506–1512, 2004[ISI][Medline]
  13. Lacroix-Triki M, Mery E, Voigt JJ, Istier L, Rochaix P. Value of cytokeratin 5/6 immunostaining using D5/16 B4 antibody in the spectrum of proliferative intraepithelial lesions of the breast. A comparative study with 34bE12 antibody. Virchows Arch 442:548–554, 2003[ISI][Medline]
  14. Leibl S, Gogg-Kammerer M, Sommersacher A, Denk H, Moinfar F. Metaplastic breast carcinomas: are they of myoepithelial differentiation?: immunohistochemical profile of the sarcomatoid subtype using novel myoepithelial markers. Am J Surg Pathol 29:347–353, 2005[CrossRef][ISI][Medline]
  15. Maisse C, Guerrieri P, Melino G. P73 and p63 protein stability: the way to regulate function?. Biochem Pharmacol 66:1555–1561, 2003[CrossRef][ISI][Medline]
  16. McKeon F. P63 and the epithelial stem cell: more than status quo?. Genes Dev 18:465–469, 2004[Free Full Text]
  17. Misdrop W, Else W, Hellmen E, Lipscomb TP. Histological classification of the mammary tumors of the dog and the cat. In: World Health Organization International Histological Classification of Tumors of Domestic Animals Schulman FY, ed. 2nd series, vol. 7, 1–59,AFIP, Washington, DC. 1999
  18. Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hu Z, Hernandez-Boussard T, Livasy C, Cowan D, Dressler L, Akslen LA, Ragaz J, Gown AM, Gilks CB, van de Rijn M, Perou CM. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 10:5367–5374, 2004[Abstract/Free Full Text]
  19. Reis-Filho JS, Milanezi F, Amendoeira I, Albergaria A, Schmitt FC. Distribution of p63, a novel myoepithelial marker, in fine-needle aspiration biopsies of the breast: an analysis of 82 samples. Cancer 99:172–179, 2003[CrossRef][ISI][Medline]
  20. Reis-Filho JS, Schmitt FC. Taking advantage of basic research: p63 is a reliable myoepithelial and stem cell marker. Adv Anat Pathol 9:280–289, 2002[CrossRef][ISI][Medline]
  21. Reis-Filho JS, Simpson PT, Martins A, Preto A, Gartner F, Schmitt FC. Distribution of p63, cytokeratins 5/6 and cytokeratin 14 in 51 normal and 400 neoplastic human tissue samples using TARP-4 multi-tumor tissue microarray. Virchows Arch 443:122–132, 2003[CrossRef][ISI][Medline]
  22. Ribeiro-Silva A, Ramalho LNZ, Garcia SB, Brandão DF, Chahud F, Zucoloto S. P63 correlates with both BRCA1 and cytokeratin 5 in invasive breast carcinomas: further evidence for the pathogenesis of the basal phenotype of breast cancer. Histopathology in press
  23. Ribeiro-Silva A, Ramalho LNZ, Garcia SB, Zucoloto S. Is p63 reliable in detecting microinvasion in ductal carcinoma in situ of the breast?. Pathol Oncol Res 9:20–23, 2003[ISI][Medline]
  24. Ribeiro-Silva A, Ramalho LNZ, Garcia SB, Zucoloto S. The relationship between p63 and p53 expression in normal and neoplastic breast tissue. Arch Pathol Lab Med 127:336–340, 2003[ISI][Medline]
  25. Signoretti S, Waltregny D, Dilks J, Isaac B, Lin D, Garraway L, Yang A, Montironi R, McKeon F, Loda M. P63 is a prostate basal cell marker and is required for prostate development. Am J Pathol 157:1769–1775, 2000[Abstract/Free Full Text]
  26. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Eystein Lonning P, Borresen-Dale AL. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 98:10869–10874, 2001[Abstract/Free Full Text]
  27. Stefanou D, Batistatou A, Nonni A, Arkoumani E, Agnantis NJ. P63 expression in benign and malignant breast lesions. Histol Histopathol 19:465–471, 2004[ISI][Medline]
  28. Trink B, Okami K, Wu L, Sriuranpong V, Jen J, Sidransky D. A new human p53 homologue. Nat Med 4:747–748, 1998[CrossRef][ISI][Medline]
  29. van de Rijn M, Perou CM, Tibshirani R, Haas P, Kallioniemi O, Kononen J, Torhorst J, Sauter G, Zuber M, Kochli OR, Mross F, Dieterich H, Seitz R, Ross D, Botstein D, Brown P. Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome. Am J Pathol 161:1991–1996, 2002[Abstract/Free Full Text]
  30. Wang X, Mori I, Tang W, Nakamura M, Nakamura Y, Sato M, Sakurai T, Kakudo K. P63 expression in normal, hyperplastic and malignant breast tissues. Breast Cancer 9:216–219, 2002[Medline]
  31. Westfall MD, Pietenpol JA. P63: Molecular complexity in development and cancer. Carcinogenesis 25:857–864, 2004[Abstract/Free Full Text]
  32. Yang A, Kaghad M, Wang Y, Gillett E, Fleming MD, Dotsch V, Andrews NC, Caput D, McKeon F. P63, a p53 homolog at 3q27–29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. Mol Cell 2:305–316, 1998[CrossRef][ISI][Medline]
Request reprints from Prof.Dr. Leandra Náira Zambelli Ramalho, Department of Pathology, Faculty of Medicine of Ribeirão Preto, Avenida Bandeirantes 3900, Campus Universitário Monte Alegre, 14049-900, Ribeirão Preto, São Paulo, Brazil. E-mail: lramalho{at}fmrp.usp.br





This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ramalho, L. N. Z.
Right arrow Articles by Zucoloto, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ramalho, L. N. Z.
Right arrow Articles by Zucoloto, S.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS